跳至主要内容
临床试验/NCT05878678
NCT05878678招募中2 期

Prospective Phase II Randomized Clinical Study of the Accuracy of Multi-modal Guided Particle Radiotherapy for Postoperative Breast Cancer With Different Arm Position

Shanghai Proton and Heavy Ion Center1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2023年5月15日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
200
试验地点
1
主要终点
The accuracy of multi-modal guided particle radiotherapy for postoperative breast cancer with different immobilization position

研究概览

简要总结

The optical body surface image (C-RAD) was used to guide and track the change of positions, and multimodal images (including 2D X-ray images, CT images and PET-CT images) were used to verify the treatment positions. In order to explore the accuracy of breast cancer patients' treatment positions and its impact on dose of the new fixation device in two different fixed positions of arm up and arm down, optimize the position fixed equipment and methods of particle radiotherapy for breast cancer, and then establish the precision process of particle radiotherapy for breast cancer under the guidance of multimodal images. In a word, this is a dosimetry and prospective Phase II randomized clinical study of the accuracy of multi-modal guided particle radiotherapy for postoperative breast cancer with different arm position.

详细描述

PET-CT: Positron Emission Tomography - Computed Tomography CT: Computed Tomography

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Patients with pathologically (cytological or histological) confirmed breast cancer with positive lymph nodes and postoperative adjuvant radiotherapy
  • Exclude distant metastasis
  • No ipsilateral breast and breast radiation therapy
  • Exclude patients requiring axillary irradiation
  • Age 18-80 years old
  • General good health (Eastern Cooperative Oncology Group, ECOG 0-2)
  • No complications such as severe pulmonary hypertension, cardiovascular disease, peripheral vascular disease, or severe chronic heart disease that may affect radiotherapy.
  • Non-pregnant (confirmed by serum or urine β-HCG test) or lactating women
  • Patients must sign informed consent to receive radiotherapy.

排除标准

  • Pathology unapproved breast cancer
  • With distant metastasis
  • The ipsilateral breast or breast has received radiation therapy
  • Patients requiring axillary irradiation
  • The dose limit of organs at risk cannot reach the preset safe dose limit
  • Pregnancy (confirmed by serum or urine β-HCG test) or lactation
  • Poor general health, Karnofsky Performance Status (KPS)<70,or ECOG>2
  • Severe complications that may affect radiotherapy, including: a) Unstable angina pectoris, congestive heart failure, myocardial infarction requiring hospitalization in the past 6 months, b) acute bacterial or systemic fungal infection, c) hospitalization for exacerbations of chronic obstructive pulmonary disease (COPD) or other respiratory diseases
  • Unable to understand the purpose of treatment or unwilling to sign the treatment consent

结局指标

主要结局

The accuracy of multi-modal guided particle radiotherapy for postoperative breast cancer with different immobilization position

时间窗: within 3 months after radiotherapy

The optical body surface image (C-RAD) was used to guide and track the change of positions, and multimodal images (including 2D X-ray images, CT images and PET-CT images) were used to verify the treatment positions. In order to explore the accuracy of breast cancer patients' treatment positions and its impact on dose of the new fixation device in two different fixed positions of arm up and arm down, optimize the position fixed equipment and methods of particle radiotherapy for breast cancer, and then establish the precision process of particle radiotherapy for breast cancer under the guidance of multimodal images.

次要结局

  • Acute toxicities(within 3 months after radiotherapy)
  • Overall survival rate(at 5 years post radiotherapy)
  • Tumor local control rate(at 5 years post radiotherapy)
  • Progression free survival rate(at 5 years post radiotherapy)
  • Late toxicities(> 3 months after radiotherapy)

研究者

发起方
Shanghai Proton and Heavy Ion Center
申办方类型
Other
责任方
Principal Investigator
主要研究者

Qing Zhang,MD

Professor

Shanghai Proton and Heavy Ion Center

研究点 (1)

Loading locations...

相似试验